Insomnia pada pasien tumor otak primer: peran dosis deksametason
https://doi.org/10.22146/bns.v21i1.110418 Nauvaldi Sasongkojati(1*), Ahmad Asmedi(2), Amelia Nur Vidyanti(3)
(1) Universitas Gadjah Mada
(2) Departemen Neurologi Fakultas Kedokteran, Kesehatan Masyarakat, dan Keperawatan, Universitas Gadjah Mada, Yogyakarta/ RSUP Dr Sardjito
(3) Departemen Neurologi Fakultas Kedokteran, Kesehatan Masyarakat, dan Keperawatan, Universitas Gadjah Mada, Yogyakarta/ RSUP Dr Sardjito
(*) Corresponding Author
Abstract
Background: Primary brain tumor affects morbidity and mortality at all ages. Insomnia has been knowned as the side effect of dexamethasone used in a primary brain tumor management. However, the relationship between dexamethasone dosage with insomnia in primary brain tumor patients remain uncertain.
Objective: This study aims to understand the relationship between dexamethasone dosage and insomnia in primary brain tumor patients at Dr. Sardjito General Hospital, Yogyakarta.
Methods: This study applied an analytical observational design using a retrospective cohort method. Data were obtained from oncology case report form (CRF) and medical records of primary brain tumor patients treated at Dr. Sardjito General Hospital, Yogyakarta from May to November of 2024. The studied variables included demographic, clinical, as well as insomnia data obtained from a questionnaire based on ICD-10 criteria. Bivariate and receiver operating characteristic (ROC) curve statistical analysis were carried out.
Results: Among 62 patients fulfilled the inclusion and exclusion criterias, the mean age was 46.4±12.7 years, with 53.2% among them were female. Data analysis showed that the dexamethasone dosage significantly affects insomnia in primary brain tumor patients (RR: 2.25; 95%CI 1.33-3.81; p <0.001).
Conclusion: There was a significant association between dexamethasone dosage and insomnia in primary brain tumor patients. This research findings may serve as the basis of insomnia management in primary brain tumor patients.
ABSTRAK
Latar Belakang: Tumor otak primer memengaruhi morbiditas dan mortalitas segala usia. Insomnia diketahui sebagai efek samping deksametason sebagai tatalaksana tumor otak primer. Namun, hubungan antara dosis deksametason dengan kejadian insomnia pada pasien tumor otak primer belum banyak diteliti.
Tujuan: Penelitian ini memiliki tujuan untuk mengetahui hubungan dosis deksametason terhadap kejadian insomnia pada pasien tumor otak primer di RSUP Dr. Sardjito Yogyakarta.
Metode: Penelitian ini dilakukan dengan studi observasional analitik menggunakan metode kohort retrospektif. Data diperoleh dari case report form (CRF) onkologi dan rekam medis pasien tumor otak primer yang di rawat inap di RSUP Dr. Sardjito pada periode Mei–November 2024. Variabel yang diteliti meliputi data demografi, klinis, dan hasil skrining insomnia menggunakan kuesioner berdasarkan kriteria ICD-10. Analisis data menggunakan uji statistik bivariat dan kurva receiver operating characteristic (ROC).
Hasil: Dari 62 pasien yang memenuhi kriteria inklusi dan eksklusi, rata-rata usia pasien sebesar 46,4±12,7 tahun, dengan 53,2% diantaranya pasien perempuan. Analisis menunjukkan dosis deksametason berpengaruh secara signifikan terhadap kejadian insomnia pada pasien tumor otak primer (RR: 2,25; 95%CI 1,33-3,81; p <0,001).
Kesimpulan: Terdapat hubungan antara dosis deksametason terhadap kejadian insomnia pada pasien tumor otak primer. Hasil penelitian ini dapat digunakan sebagai dasar penatalaksanaan insomnia pada pasien tumor otak primer.
Keywords
Full Text:
PDF (Bahasa Indonesia)References
Park SH, Won J, Kim SI, Lee Y, Park CK, Kim SK, et al. Molecular testing of brain tumor. Journal of Pathology and Translational Medicine. 2017 May 12;51(3):205-23.
Farmanfarma KK, Mohammadian M, Shahabinia Z, Hassanipour S, Salehiniya H. Brain cancer in the world: an epidemiological review. World Cancer Res J. 2019 Jan;6(5):1-5.
de Robles P, Fiest KM, Frolkis AD, Pringsheim T, Atta C, St. Germaine-Smith C, et al. The worldwide incidence and prevalence of primary brain tumors: a systematic review and meta-analysis. Neuro-oncology. 2015 Jun 1;17(6):776-83.
Lacy J, Saadati H, James BY. Complications of brain tumors and their treatment. Hematology/oncology clinics of North America. 2012 Aug 1;26(4):779-96.
Savard J, Savard MH. Insomnia and cancer: prevalence, nature, and nonpharmacologic treatment. Sleep Medicine Clinics. 2013 Sep 1;8(3):373-87.
Zarogoulidis P, Petridis D, Kosmidis C, Sapalidis K, Nena L, Matthaios D, et al. Immunotherapy and chemotherapy versus sleep disturbances for NSCLC patients. Current Oncology. 2023 Feb 6;30(2):1999-2006.
Willis KD, Ravyts SG, Lanoye A, Loughan AR. Sleep disturbance in primary brain tumor: prevalence, risk factors, and patient preferences. Supportive Care in Cancer. 2022 Jan;30(1):741-8.
Levenson JC, Kay DB, Buysse DJ. The pathophysiology of insomnia. Chest. 2015 Apr 1;147(4):1179-92.
Cunnington D, Junge MF, Fernando AT. Insomnia: prevalence, consequences and effective treatment. Medical Journal of Australia. 2013 Oct;199:S36-40.
Robertson ME, McSherry F, Herndon JE, Peters KB. Insomnia and its associations in patients with recurrent glial neoplasms. Springerplus. 2016 Jun 21;5(1):823.
Kostaras X, Cusano F, Kline GA, Roa W, Easaw J. Use of dexamethasone in patients with high-grade glioma: a clinical practice guideline. Current oncology. 2014 Jun;21(3):e493.
Sturdza A, Millar BA, Bana N, Laperriere N, Pond G, Wong RK, et al. The use and toxicity of steroids in the management of patients with brain metastases. Supportive Care in Cancer. 2008 Sep;16(9):1041-8.
Cole JL. Steroid-induced sleep disturbance and delirium: a focused review for critically ill patients. Federal Practitioner. 2020 Jun;37(6):260.
Bordag N, Klie S, Jürchott K, Vierheller J, Schiewe H, Albrecht V, et al. Glucocorticoid (dexamethasone)-induced metabolome changes in healthy males suggest prediction of response and side effects. Scientific reports. 2015 Nov 3;5(1):15954.
Ren CY, Rao JX, Zhang XX, Zhang M, Xia L, Chen GH. Changed signals of blood adenosine and cytokines are associated with parameters of sleep and/or cognition in the patients with chronic insomnia disorder. Sleep Medicine. 2021 May 1;81:42-51.
Mai E, Buysse DJ. Insomnia: prevalence, impact, pathogenesis, differential diagnosis, and evaluation. Sleep medicine clinics. 2008 Jun 1;3(2):167-74.
Nugent SM, Lovejoy TI, Shull S, Dobscha SK, Morasco BJ. Associations of pain numeric rating scale scores collected during usual care with research administered patient reported pain outcomes. Pain Medicine. 2021 Oct 1;22(10):2235-41.
Lin PC, Chen PY, Wei KC, Lin JH, Lin MR, Wang HC, et al. Sleep disturbance in adults with untreated primary brain tumors: prevalence and impact on quality of life. Sleep and Biological Rhythms. 2023 Apr;21(2):201-9.
Jeon MS, Dhillon HM, Koh ES, Nowak AK, Hovey E, Descallar J, et al. Exploring sleep disturbance among adults with primary or secondary malignant brain tumors and their caregivers. Neuro-oncology practice. 2021 Feb 1;8(1):48-59.
Armstrong TS, Vera-Bolanos E, Acquaye AA, Gilbert MR, Ladha H, Mendoza T. The symptom burden of primary brain tumors: evidence for a core set of tumor-and treatment-related symptoms. Neuro-oncology. 2015 Aug 19;18(2):252-60.
King AL, Shuboni-Mulligan DD, Vera E, Crandon S, Acquaye AA, Boris L, et al. Exploring the prevalence and burden of sleep disturbance in primary brain tumor patients. Neuro-oncology practice. 2022 Dec 1;9(6):526-35.
Jessurun CA, Hulsbergen AF, Lamba N, Tewarie RD, Smith TR, Broekman ML. Practice variation in perioperative steroid dosing for brain tumor patients: an international survey. World Neurosurgery. 2022 Mar 1;159:e431-41.
Scheffler P, Fung C, Momjian S, Koessinger D, Häni L, Neidert N, Straehle J, Volz F, Schnell O, Beck J, El Rahal A. Dexamethasone in patients with glioblastoma: A systematic review and meta-analysis. Cancers. 2024 Apr 1;16(7):1393.
Lee BN, Dantzer R, Langley KE, Bennett GJ, Dougherty PM, Dunn AJ, et al. A cytokine-based neuroimmunologic mechanism of cancer-related symptoms. Neuroimmunomodulation. 2004 Aug 20;11(5):279-92.
Gorgulu Y, Caliyurt O, Kose Cinar R, Sonmez MB. Acute sleep deprivation immediately increases serum GDNF, BDNF and VEGF levels in healthy subjects. Sleep and Biological Rhythms. 2022 Jan;20(1):73-9.
Zielinski MR, Krueger JM. Sleep and innate immunity. Frontiers in bioscience (Scholar edition). 2011 Jan;3(2):632-642.
Wang GY, Zhu ZM, Cui S, Wang JH. Glucocorticoid induces incoordination between glutamatergic and GABAergic neurons in the amygdala. PLoS One. 2016 Nov 18;11(11):e0166535.
Savage RA, Zafar N, Yohannan S, Miller JM. Melatonin. InStatPearls [Internet] 2024 Feb 9. StatPearls Publishing.
Liu D, Yu C, Huang K, Thomas S, Yang W, Liu S, Kuang J. The Association between Hypertension and Insomnia: A Bidirectional Meta‐Analysis of Prospective Cohort Studies. International journal of hypertension. 2022;2022(1):4476905.
Korabelnikova EA, Danilov AB, Danilov AB, Vorobyeva YD, Latysheva NV, Artemenko AR. Sleep disorders and headache: a review of correlation and mutual influence. Pain and therapy. 2020 Dec;9(2):411-25.
López E, de la Torre-Luque A, Lazo A, Álvarez J, Buela-Casal G. Assessment of sleep disturbances in patients with cancer: Cross-sectional study in a radiotherapy department. European Journal of Oncology Nursing. 2016 Feb 1;20:71-6.
Surani S, Brito V, Surani A, Ghamande S. Effect of diabetes mellitus on sleep quality. World journal of diabetes. 2015 Jun 25;6(6):868.
DOI: https://doi.org/10.22146/bns.v21i1.110418
Article Metrics
Abstract views : 31
| 
views : 19
Refbacks
- There are currently no refbacks.
Copyright (c) 2026 Berkala NeuroSains
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.